## AZN: Astrazeneca PLC - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.5% below STRENGTH zone (3.0-6.0%); PEG 1.03 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.3% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($88.32)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 2, Bearish: 1)

**1. Is the Market Bullish or Bearish on AstraZeneca PLC?**
- Source: Sahm | 20251218T000942 | Somewhat-Bullish | Relevance: 100%
- Short interest in AstraZeneca PLC (NYSE: AZN) has decreased by 6.25% since its last report, with 9.19 million shares currently sold short, representing 0.3% of available shares. This decline in short interest suggests a potentially more bullish sentiment among investors for the stock. Compared to its peers, AstraZeneca PLC has less short interest, averaging 3.75%.

**2. REG - AstraZeneca PLC - Subcutaneous Saphnelo approved in EU**
- Source: TradingView â€” Track All Markets | 20251217T000952 | Bullish | Relevance: 100%
- AstraZeneca's Saphnelo (anifrolumab) has received EU approval for subcutaneous self-administration as a pre-filled pen for adult systemic lupus erythematosus (SLE) patients. This approval, based on the Phase III TULIP-SC trial, offers a convenient at-home treatment option with the same clinical benefits as the intravenous infusion. The new formulation aims to broaden patient access to this important medicine, especially since many SLE patients on biologics prefer subcutaneous self-administration.

**3. AstraZeneca Fails to Block Colorado Contract Pharmacy Regulation**
- Source: Bloomberg Law News | 20251218T180000 | Bearish | Relevance: 100%
- AstraZeneca PLC was denied a request by the US District Court for the District of Colorado to temporarily block the state's 340B Contract Pharmacy Protection Act. The drugmaker had argued that federal law should prevent Colorado from imposing additional conditions on the distribution of federally discounted drugs. This setback marks another challenge for AstraZeneca in its efforts to navigate state-specific regulations concerning drug pricing programs.

**4. Assenagon Asset Management S.A. Sells 569,162 Shares of AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251218T080942 | Somewhat-Bullish | Relevance: 100%
- Assenagon Asset Management S.A. significantly reduced its stake in AstraZeneca PLC by 48.7%, selling 569,162 shares and now holding 598,354 shares valued at approximately $45.91 million. Despite this sale, analysts maintain a "Moderate Buy" consensus rating for AstraZeneca with a price target of $95.75, following the company's recent strong quarterly earnings performance. The biopharmaceutical company reported beating EPS and revenue estimates, with its stock trading near $89.86 and a market capitalization of $278.7 billion.

**5. Rep. Gilbert Ray Cisneros, Jr. Buys AstraZeneca PLC (NASDAQ:AZN) Stock**
- Source: MarketBeat | 20251217T220952 | Somewhat-Bullish | Relevance: 100%
- Representative Gilbert Ray Cisneros, Jr. (D-California) recently purchased between $1,001 and $15,000 of AstraZeneca PLC (NASDAQ:AZN) stock on November 19th. This transaction was disclosed on December 15th and occurred in his "150 MAIN STREET TRUST > BANK OF AMERICA" account. AstraZeneca shares traded near $89.86 with a market capitalization of about $278.7 billion, and analysts currently hold a "Moderate Buy" rating with a consensus price target around $95.75.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.3% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.03 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $283.3B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.03 |
| Forward P/E | 17.7 |
| Current P/E | 19.9 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.9% to 0.5% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.5pp (needs >3.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. OFD pattern: +MUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.52% (CS: 64) | Neutral |
| RSI_14 | 56.7 | Neutral |
| MACD Histogram | -0.27 | Bearish |
| vs SMA20 | 1.003x | Above |
| vs SMA50 | 1.045x | Above |
| vs SMA200 | 1.184x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $91.36
- **Stop Loss:** $88.32 (3.3% risk)
- **Target:** $94.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 394
- **Position Value:** $35,995.84
- **Portfolio %:** 36.00%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*